Dr. Sanz-Altamira is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5 Branch Street
Methuen, MA 01844Phone+1 978-620-2020Fax+1 617-394-2635
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 1995 - 1998
Newton-Wellesley HospitalResidency, Internal Medicine, 1992 - 1995
Medizinische Hochschule HannoverPhD, Experimental Nephrology, 1989 - 1990
Universidad de Sevilla FOMClass of 1988
Certifications & Licensure
NH State Medical License 1998 - 2026
MA State Medical License 1994 - 2025
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012-2013
- Super Doctor SuperDoctors.com
- Top MD Consumers Checkbook
Clinical Trials
- Collection of Blood Specimens for Circulating Tumor Cell Analysis Start of enrollment: 2013 Sep 30
- SURGE: Supporting UnderRepresented Minorities in Genomics-based Cancer Trial Enrollment (Intervention) Start of enrollment: 2023 Apr 03
Roles: Principal Investigator, Contact
- STOP-HER2: Stopping Trastuzumab in HER2+ MBC Start of enrollment: 2023 Apr 19
Roles: Contact, Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsA novel colony stimulating factor 3 receptor activating mutation identified in a patient with chronic neutrophilic leukemia.Breanna N Maniaci, Jooho Chung, Pedro Sanz-Altamira, Daniel J DeAngelo, Julia E Maxson
Haematologica. 2023-07-01 - 18 citationsProspective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapyPaul J. Hesketh, Pedro Sanz-Altamira, Julie Bushey, Ann M. Hesketh
Supportive Care in Cancer. 2012-05-01 - 26 citationsAprepitant, dexamethasone, and palonosetron in the prevention of doxorubicin/cyclophosphamide-induced nausea and vomitingPaul J. Hesketh, Pedro Sanz-Altamira
Supportive Care in Cancer. 2012-03-01
Press Mentions
New Data Published in JAAOS Demonstrates Breakthrough Therapy ZetaFuse® as a Potential Treatment for Degenerative Disc Disease in Late-Stage Cancer PatientsSeptember 24th, 2024- SURGE: Supporting UnderRepresented Minorities in Genomics-Based Cancer Trial Enrollment (Intervention)May 16th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
